HDAC4 Cancer Research Results
HDAC4, Histone deacetylases: Click to Expand ⟱
| Source: |
| Type: |
HDAC4 overexpression is associated with higher tumor grade, advanced clinical stage and poor survival. HDAC4 promotes proliferation and G1/S cell cycle progression in EC cells by inhibiting cyclin-dependent kinase (CDK) inhibitors p21 and p27 and up-regulating CDK2/4 and CDK-dependent Rb phosphorylation.
HDAC4 is often overrepresented and associated with poor prognosis.
HDAC Inhibitors: Given the role of HDAC4 in cancer, HDAC inhibitors (HDACi) are being explored as potential therapeutic agents.
|
AML, Acute Myeloid Leukemia: Click to Expand ⟱
Scientific Papers found: Click to Expand⟱
HDAC4↓, NRF2↓, p‑NRF2↓, miR-133a-3p↑, miR-206↑,
| - |
in-vitro, |
BC, |
MDA-MB-468 |
|
|
|
- |
in-vitro, |
AML, |
JK |
|
|
|
UHRF1↓, DNMT1↓, DNMT3A↓, DNMTs↓, HDAC1↓, HDAC4↓, HDAC↓, DLC1↑, PPARγ↑, FOXO↑, TET2↑, CYP1B1↑, G9a↓,
Showing Research Papers: 1 to 2 of 2
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress ⓘ
NRF2↓, 1, p‑NRF2↓, 1,
Core Metabolism/Glycolysis ⓘ
PPARγ↑, 1,
DNA Damage & Repair ⓘ
CYP1B1↑, 1, DNMT1↓, 1, DNMT3A↓, 1, DNMTs↓, 1, G9a↓, 1, UHRF1↓, 1,
Proliferation, Differentiation & Cell State ⓘ
FOXO↑, 1, HDAC↓, 1, HDAC1↓, 1, HDAC4↓, 2,
Migration ⓘ
DLC1↑, 1, miR-133a-3p↑, 1, miR-206↑, 1,
Drug Metabolism & Resistance ⓘ
TET2↑, 1,
Total Targets: 17
Pathway results for Effect on Normal Cells:
Total Targets: 0
Scientific Paper Hit Count for: HDAC4, Histone deacetylases
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:2 Cells:% prod#:% Target#:407 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid
Home Page